NCT00889564已完成不适用
HeRO Vascular Access Device Bacteremia Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 14
- 主要终点
- HeRO superiority in device and implant procedure-related bacteremia compared to historical tunneled dialysis catheter literature control
研究概览
简要总结
The purpose of this study is to compare the safety and effectiveness of the HeRO Vascular Access Device in access challenged (e.g., catheter-dependent) hemodialysis patients. It is hypothesized the bacteremia rate associated with the HeRO device will be lower than a historical literature control of tunneled dialysis catheters.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •21 years of age or older.
- •Male or non-pregnant female.
- •Life expectancy less than 1 year.
- •ESRD on hemodialysis with poor remaining venous access sites for creation of an AV fistula or placement of a graft in the upper extremities.
- •Implant side central venous system that surgeon believes can be accessed with interventional devices and can accommodate the 19 Fr GVAS device.
- •Potential GVAS target brachial artery ≥ 3 mm in diameter determined by any suitable measure.
- •Ability to understand and provide written informed consent.
- •Willing and able to cooperate with follow-up examinations.
排除标准
- •Documented history of drug abuse within six months prior to enrollment.
- •"Planned" concomitant surgical procedure or previous major surgery within 30 days, excluding vascular access related procedures.
- •Currently being treated with another investigational device or drug.
- •Known bleeding diathesis or hypercoaguable state.
- •Peripheral white blood cell count 1.5 K/mm3 or platelet count 50 K/mm
- •Degenerative connective tissue disease, e.g., Marfan's and Ehlers Danlos Syndrome. Subjects with Lupus Erythematosus may be enrolled if receiving no immunosuppressants or low dose prednisone only (< 10 mg/day orally).
- •Subjects with known or suspected concomitant active bacterial, fungal, viral, or parasitic infection. Subjects with Hepatitis B and/or Hepatitis C may be enrolled. Subjects who are HIV + with CD4 count of < 200 are excluded. Subjects with bacteremia within the past six (6) weeks must have negative blood cultures one week after completing appropriate antibiotic therapy prior to enrollment.
- •Severe underlying co-morbidity or immediate life-threatening condition.
- •Subjects with any condition which, in the opinion of the investigator, could preclude evaluation of response or completion of follow-up or affect subject safety.
- •Subjects with significant arterial occlusive disease which would preclude safe placement of an upper extremity hemodialysis access.
- •Subjects with history or findings on physical examination suggesting significant arterial insufficiency that could affect patient safety and/or device performance in the extremity planned for use with GVAS (i.e., steal syndrome, hand ischemia, peripheral arterial vascular disease, etc.).
- •Subjects with scheduled kidney transplant within the next 12 months.
- •Subjects with history of superior vena cava syndrome are excluded unless it was induced by previous access (these subjects can be enrolled).
- •Subjects with history of decreased cardiac output with ejection fraction < 20% and/or NYHA class III or IV. NYHA definitions: Class III - Subjects with marked limitation of activity; they are comfortable only at rest; Class IV - Subjects who should be at complete rest, confined to bed or chair; any physical activity brings on discomfort and symptoms occur at rest.
- •Subjects with history of uncorrected hypotension with systolic blood pressures routinely < 100 mg Hg.
- •Subjects who currently have a pacemaker or ICD in their central venous system on the same side where the GVAS device would be implanted.
结局指标
主要结局
HeRO superiority in device and implant procedure-related bacteremia compared to historical tunneled dialysis catheter literature control
时间窗: 12 months
次要结局
- Incidence of serious device or implant procedure-related serious adverse events and loss of secondary patency(12 months)
研究者
研究点 (14)
Loading locations...
相似试验
已完成
不适用
HeRO Vascular Access Device Post Market Procedural Survey ProtocolEnd Stage Renal DiseaseNCT00889291Merit Medical Systems, Inc.77
终止
不适用
Preventing Catheter-related Bacteremia When Administering Injectable Medications in Premature Infants.Infant, Very Low Birth WeightBacteremiaNCT02633124University Hospital, Lille87
招募中
不适用
Efficacy and Safety Evaluation of Vi-sealerBenign Gynecologic NeoplasmNCT05629611Hyun Park280
已完成
不适用
Safety and Performance Study of Large Hole Vascular Closure DevicePercutaneous Closure of Arteriotomy in Common Femoral ArteryNCT01943344Vivasure Medical Limited12
已完成
不适用
ACtive Catheterization for EndovaScular TreatmentSUnruptured Intracranial AneurysmArteriovenous Cerebral MalformationsCarotid StenosisNCT05355259Basecamp Vascular10